Drug intelligence / Profile preview

WecProB

Development stage: Unknown
Lead developer: Wecare Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

WecProB is a probiotic combination product consisting of the bacterial strains *Bifidobacterium animalis subsp. lactis* and *Lacticaseibacillus rhamnosus*. It is developed by Wecare Probiotics and has been investigated for its potential therapeutic effects in children with Attention Deficit Hyperactivity Disorder (ADHD). The rationale for using WecProB in ADHD is based on the gut-brain axis hypothesis, suggesting that specific probiotic strains can modulate the intestinal microbiota, influence neurotransmitter production, and reduce systemic inflammation, thereby potentially improving behavioral symptoms and cognitive function.

Brand names: WecProB
Other names: Bifidobacterium animalis subsp. lactis + Lacticaseibacillus rhamnosus

Beyond the preview

Go deeper on WecProB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WecProB.

Explore the full profile